Oramed Pharmaceuticals ORMP Insider Ownership

NASDAQ ORMP

$4.15 +0.09 (+2.22%)

At close: Oct 20, 2026 · 4:00 PM EDT

Insider Holdings by Owner

9.48Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

21.40%

▲+3.56% pp QoQ

Shares Held by Insiders

8.84Mn

filed for Sep 2026

▲+19.94% QoQ

Shares Outstanding

41.31Mn

41,314,211 shares

Direct Holdings

8.57Mn

Indirect: 264.89K

Net Shares Traded (QoQ)

+1.47Mn

net buying in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 10, 2026

Over the past year, ORMP insiders sold $1.17 million of stock (260.36K shares) on the open market and bought none.

Oramed Pharmaceuticals' open-market sales in the past 12 months came from 2 insiders; no insider bought.
The largest open-market sales of ORMP in the past 12 months were by Joshua Hexter (COO & CBO), totaling $746,761 (167K shares), most recently on October 1, 2026.
Outside the open market, Oramed Pharmaceuticals insiders received 2.61Mn shares in stock awards, acquired 178K shares through option exercises and conversions, gave up 479.9K shares to cover taxes or exercise prices and gave away 186.17K shares as gifts over the past 12 months.
Per Business Quant, ORMP insiders together hold 8.79Mn shares based on their latest Form 4 filings, up 19.26% from 7.37Mn shares at the end of Q2 2026 and up 36.54% from 6.44Mn shares at the end of Q3 2025.
Indirect holdings, through trusts, partnerships, family members and other entities, make up 3.01% (264.89K shares) of Oramed Pharmaceuticals' insider total, with the other 96.99% (8.52Mn shares) held directly.
The insider holdings in Oramed Pharmaceuticals belong to 9 insiders who have reported on Form 4 within the past two years.
Oramed Pharmaceuticals' three largest insider shareholders, based on their latest Form 4 filings, are Nadav Kidron (President and CEO, 4.27Mn shares), Miriam Kidron (Chief Scientific Officer, 1.55Mn shares) and Joshua Hexter (COO & CBO, 1.33Mn shares).
Of the shares held by ORMP insiders, 48.54% belong to Nadav Kidron.
Institutions held 36.00% of Oramed Pharmaceuticals' outstanding shares in their Q2 2026 13F filings, insiders about 21.27% based on their latest Form 4 filings, and other investors, including the public, the remaining 42.73%.
Over the trailing 12 months, 8 insiders reported transactions in ORMP stock across 28 Form 4 filings.
This summary of Oramed Pharmaceuticals insider activity covers Form 4 filings through October 2, 2026.

Form 4 Holdings

Insiders Holding ORMP

Insiders 15

Shares held 9.48Mn

Of outstanding 22.94%

#	Insider	Position	Direct	Total	Share of Insiders	Last Filed
1	Nadav Kidron	President And Ceo	4,140,505	4,140,505	43.7%	25 Sep, 2026
2	Miriam Kidron	Chief Scientific Officer	1,550,554	1,550,554	16.4%	25 Sep, 2026
3	Joshua Hexter	Coo Cbo	1,328,130	1,328,130	14.0%	02 Oct, 2026
4	Avraham Gabay	Chief Financial Officer	861,076	861,076	9.1%	02 Oct, 2026
5	David Silberman	Chief Financial Officer	366,500	366,500	3.9%	08 Jan, 2024
6	Arie Mayer	Director	168,009	168,009	1.8%	05 Jan, 2026
7	Yadin Rozov	Director	155,320	155,320	1.6%	08 Jan, 2024
8	Netanel Derovan	Chief Legal Officer	149,500	149,500	1.6%	31 May, 2023
9	Leonard Sank	Director	134,531	134,531	1.4%	09 Jun, 2025
10	Michael Rabinowitz	Chief Commercial Officer	126,143	126,143	1.3%	04 Jan, 2023
11	Benjamin Shapiro	Director	123,220	123,220	1.3%	05 Jan, 2026
12	Daniel Aghion	Director	113,441	113,441	1.2%	02 Jan, 2026
13	Michael Rabinowitz	Chief Commercial Officer	109,468	109,468	1.2%	05 Jan, 2022
14	Yehuda Reznick	Director	105,180	105,180	1.1%	05 Jan, 2026
15	Kevin Rakin	Director	46,661	46,661	0.5%	22 Mar, 2022

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

407 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
01 Oct, 2026	Avraham Gabay	Chief Financial Officer	Disposed S	20,000	$4.51	$90.20K	861,076	Direct
01 Oct, 2026	Joshua Hexter	Coo Cbo	Disposed S	30,000	$4.51	$135.33K	1,328,130	Direct
24 Sep, 2026	Nadav Kidron	President And Ceo	Acquired A	349,497	—	—	3,771,740	Direct
24 Sep, 2026	Avraham Gabay	Chief Financial Officer	Acquired A	209,291	—	—	881,076	Direct
24 Sep, 2026	Miriam Kidron	Chief Scientific Officer	Acquired A	208,125	—	—	1,341,263	Direct
24 Sep, 2026	Joshua Hexter	Coo Cbo	Acquired A	75,455	—	—	1,148,839	Direct
24 Sep, 2026	Nadav Kidron	President And Ceo	Acquired A	368,765	—	—	4,140,505	Direct
24 Sep, 2026	Joshua Hexter	Coo Cbo	Acquired A	209,291	—	—	1,358,130	Direct
24 Sep, 2026	Miriam Kidron	Chief Scientific Officer	Acquired A	209,291	—	—	1,550,554	Direct
24 Sep, 2026	Miriam Kidron	Chief Scientific Officer	Disposed D	104,000	—	—	0	Direct
24 Sep, 2026	Joshua Hexter	Coo Cbo	Disposed D	50,000	—	—	0	Direct
24 Sep, 2026	Miriam Kidron	Chief Scientific Officer	Disposed D	100,000	—	—	0	Direct
24 Sep, 2026	Nadav Kidron	President And Ceo	Disposed D	196,500	—	—	0	Direct
24 Sep, 2026	Joshua Hexter	Coo Cbo	Disposed D	50,000	—	—	0	Direct
24 Sep, 2026	Nadav Kidron	President And Ceo	Disposed D	190,000	—	—	0	Direct
24 Sep, 2026	Miriam Kidron	Chief Scientific Officer	Disposed D	69,999	—	—	0	Direct
24 Sep, 2026	Joshua Hexter	Coo Cbo	Disposed D	36,000	—	—	0	Direct
24 Sep, 2026	Nadav Kidron	President And Ceo	Disposed D	49,000	—	—	0	Direct
24 Sep, 2026	Miriam Kidron	Chief Scientific Officer	Disposed D	47,000	—	—	0	Direct
24 Sep, 2026	Miriam Kidron	Chief Scientific Officer	Disposed D	100,000	—	—	0	Direct

Showing 1 to 20 of 407 transactions